ArticleFrontiers in medicine2026
Qing-Re-Qu-Shi formula improves clinical outcomes and is accompanied by gut microbiota and microbial metabolite remodeling in adults with moderate atopic dermatitis: a randomized placebo-controlled multi-omics trial.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The gut-skin axis is increasingly implicated in atopic dermatitis (AD), but randomized adult studies linking clinical response to paired gut microbiome and circulating metabolite profiling remain limited. We evaluated Qing-Re-Qu-Shi formula in adults with moderate AD and examined associated microbiome and serum metabolite changes. Methods: In this randomized, double-blind, placebo-controlled 12-week trial, 152 adults with moderate AD were assigned 1:1 to Qing-Re-Qu-Shi formula or placebo. Outcomes included Eczema Area and Severity Index (EASI), SCORAD, Patient-Oriented Eczema Measure (POEM), pruritus numerical rating scale (NRS), Dermatology Life Quality Index (DLQI), and responder rates. The primary clinical analysis followed the intention-to-treat principle. Paired fecal 16S rRNA sequencing and targeted serum metabolomics were performed in the biospecimen subset. Differential feature analyses adjusted for baseline level, age, and sex; Results: All randomized participants were included in clinical analyses; 124 contributed paired fecal and serum specimens, and 102 also had week-12 clinical data for cross-domain analyses. Compared with placebo, Qing-Re-Qu-Shi produced greater week-12 improvements in EASI (adjusted mean difference, -3.78; 95% CI, -4.54 to -3.01), SCORAD (-9.73; 95% CI, -11.54 to -7.93), POEM (-3.39; 95% CI, -4.06 to -2.73), pruritus NRS (-0.94; 95% CI, -1.15 to -0.72), and DLQI (-2.86; 95% CI, -3.47 to -2.26) (all Conclusion: Qing-Re-Qu-Shi formula improved clinical severity and patient-reported outcomes in adults with moderate AD. These benefits were accompanied by selective gut microbial remodeling and circulating microbiota-related metabolite changes, supporting an associative link between clinical improvement and gut ecosystem remodeling rather than proving causality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.